Skip to main content

Evidence Amyloid Scan EEG Study (EASES)


The EASES study is a 2-year observational study designed to measure brain function during the onset and progression of mild cognitive impairment (MCI) in older adults using quantitative electroencephalography (qEEG).

Minimum Age Maximum Age Gender Healthy Volunteers
60 Years N/A All No
July 20, 2018
November 30, 2020

  • Medicare beneficiary
  • Diagnosis of MCI or dementia (with Alzheimer's being a diagnostic consideration)
  • Cognitive complaint verified by objectively confirmed cognitive impairment

  • Brain magnetic resonance imaging and/or computed tomography scan within past 2 years
  • Normal cognition or subjective complaints that are not verified by cognitive testing
  • Knowledge of amyloid status could negatively impact the participant or family
  • Scan ordered for nonmedical purposes (e.g., legal, insurance coverage, or employment screening)
  • Cancer requiring active therapy (excluding non-melanoma skin cancer)
  • Life expectancy less than 2 years
  • Residence in a skilled nursing facility

qEEG is a noninvasive technique that records the brain's electrical activity. Participants will be scanned using a device that fits around the head and has electrodes attached. Results will be analyzed to see if there's a correlation between this electrical activity and levels of amyloid, a protein that accumulates abnormally in Alzheimer's brains, as seen on positron emission tomography scans. Researchers will evaluate whether qEEG can be used to differentiate healthy aging individuals from those developing MCI to help diagnose people in the early stages of preclinical Alzheimer's disease.

Name City State Zip Status Primary Contact
Translational Cognitive Research
Houston Texas 77036 Recruiting Kenneth O. Russell

Metabolic Therapy Inc.

  • Institute of Asian American Adult Development


Quantitative EEG for Assessment of Mild Cognitive Impairment Associated With Preclinical Alzheimer's Disease - Evidence for Amyloid Indication Study